clinical trial · NCT07041099
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
SjögrenSjogren DiseaseSjogren's SyndromeCLN-978
brief summary
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
started
Oct 1, 2025
primary completion
Mar 15, 2028
completion
Mar 15, 2029
last updated
Mar 23, 2026
official title
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol